AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12693876 — intervention group
Group type: EXPERIMENTAL
Intervention: SG+ (Standard Gamble with hypothetical marker states)
Number of subjects: 84
Study 12693876 — intervention group
Group type: COMPARATOR
Intervention: SG- (Standard Gamble without hypothetical marker states)
Number of subjects: 84
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar‐supported overdenture (maxillary completely edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap‐retained overdenture (maxillary completely edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw‐retained hybrid denture (mandibular completely edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap‐retained prosthesis (mandibular completely edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw‐retained fixed partial denture (mandibular posterior partially edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw‐retained fixed partial denture (maxillary posterior partially edentulous)
Number of subjects: 687
Study 11885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented single crown (maxillary anterior single tooth)
Number of subjects: 687
Study 9398894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1 gm + Clarithromycin 500 mg (OAC500)
Number of subjects: 787
Study 9398894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Metronidazole 400 mg + Clarithromycin 250 mg (OMC250)
Number of subjects: 787
Study 9398894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Metronidazole 400 mg + Clarithromycin 500 mg (OMC500)
Number of subjects: 787
Study 9398894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1 gm + Clarithromycin 250 mg (OAC250)
Number of subjects: 787
Study 9398894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1 gm + Metronidazole 400 mg (OAM)
Number of subjects: 787
Study 9398894 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg + Placebo (OP)
Number of subjects: 787
Study 1575550 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24
Study 1575550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3872061 — intervention group
Group type: EXPERIMENTAL
Intervention: 60:40 whey/casein formula
Number of subjects: 15
Study 3872061 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate preparation
Number of subjects: 15
Study 3872061 — intervention group
Group type: COMPARATOR
Intervention: 20:80 whey/casein formula
Number of subjects: 15
Study 3872061 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake formulas (4.3 g/kg/day and 4.4 g/kg/day)
Number of subjects: 15
Study 31149913 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endotherapy
Number of subjects: 20
Study 31149913 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 20
Study 27112124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gist Reasoning Training
Number of subjects: 50
Study 27112124 — intervention group
Group type: COMPARATOR
Intervention: New Learning
Number of subjects: 50
Study 25767938 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Number of subjects: 20
Study 25767938 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscope
Number of subjects: 20
Study 24062326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed meal dosing
Number of subjects: 126
Study 24062326 — intervention group
Group type: COMPARATOR
Intervention: Flexible meal dosing
Number of subjects: 126
Study 24062326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study 22029980 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab (200 mg at weeks 0 and 4, 100 mg at week 8 and every 4 weeks thereafter)
Number of subjects: 317
Study 22029980 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (5 to 25 mg weekly)
Number of subjects: 317
Study 22029980 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab
Number of subjects: 317
Study 22029980 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 317
Study 19507267 — intervention group
Group type: EXPERIMENTAL
Intervention: Far Infrared Ray (FIR) stimulation
Number of subjects: 0
Study 19507267 — intervention group
Group type: COMPARATOR
Intervention: Heat Pad (HP) therapy
Number of subjects: 0
Study 16937305 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin (CDDP) at 30 mg/m(2) for weekly schedule
Number of subjects: 45
Study 16937305 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin (CDDP) at 50 mg/m(2) for monthly schedule
Number of subjects: 45
Study 15632875 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 3755
Study 11598313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clioquinol 20 mg/day
Number of subjects: 20
Study 11598313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clioquinol 80 mg/day
Number of subjects: 20
Study 11598313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clioquinol (both dosages)
Number of subjects: 20
Study 9531122 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow cold therapy for 3 days, then as needed for days 4-7.
Number of subjects: 100
Study 8021330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg
Number of subjects: 257
Study 8021330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 257
Study 8021330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 8021330 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 257
Study 2783753 — intervention group
Group type: COMPARATOR
Intervention: Retransfusion of oxygenator blood after termination of extracorporeal circulation (Group I)
Number of subjects: 100
Study 2783753 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of oxygenator content by means of a cell separator (Group II)
Number of subjects: 100
Study 2783753 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonation of autologous blood and isovolumetric substitution of hydroxyethyl starch (10 ml/kg bodyweight) after induction of anesthesia plus cell separator (Group III)
Number of subjects: 100
Study 2783753 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonation and use of a cell separator plus postoperative retransfusion of shed mediastinal blood (Group IV)
Number of subjects: 100
Study 1194660 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach services
Number of subjects: 0
Study 1194660 — intervention group
Group type: EXPERIMENTAL
Intervention: Free medical care + Outreach services
Number of subjects: 0
Study 1194660 — intervention group
Group type: COMPARATOR
Intervention: Free medical care
Number of subjects: 0
Study 31113400 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentive eating smartphone application along with standard dietary advice
Number of subjects: 107
Study 31113400 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice only
Number of subjects: 107
Study 31113400 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentive eating smartphone application
Number of subjects: 107
Study 28130726 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (9 weeks, group intervention)
Number of subjects: 60
Study 25452447 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I plus armodafinil (A)
Number of subjects: 96
Study 25452447 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I plus placebo (P)
Number of subjects: 96
Study 25452447 — intervention group
Group type: COMPARATOR
Intervention: Armodafinil (A) alone
Number of subjects: 96
Study 23129814 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface neuromuscular electrical stimulation (30-minute sessions) and physiotherapy (45 minutes)
Number of subjects: 90
Study 23129814 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapy for 45 minutes)
Number of subjects: 90
Study 21968267 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine therapy
Number of subjects: 43
Study 21968267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 17559710 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 40
Study 17559710 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS of the occipital cortex (active control)
Number of subjects: 40
Study 17559710 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (placebo control)
Number of subjects: 40
Study 16864930 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus ACEI (n=13)
Number of subjects: 28
Study 16864930 — intervention group
Group type: COMPARATOR
Intervention: ACEI only (n=15)
Number of subjects: 28
Study 12518131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tube insertion
Number of subjects: 157
Study 12518131 — intervention group
Group type: COMPARATOR
Intervention: No rectal tube insertion
Number of subjects: 157
Study 11737118 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3/MMF/delayed Neoral/prednisone
Number of subjects: 54
Study 11737118 — intervention group
Group type: COMPARATOR
Intervention: MMF/immediate Neoral/prednisone without OKT3
Number of subjects: 54
Study 9416409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT)
Number of subjects: 63
Study 9416409 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative photodynamic therapy (no PDT)
Number of subjects: 63
Study 8440925 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal disease associated with specific pathologic processes
Number of subjects: 25
Study 8440925 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HIV‐1 mRNA
Number of subjects: 25
Study 8440925 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HIV‐1 in esophageal mucosa
Number of subjects: 25
Study 3359863 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential reinforcement for the use of foreign vocabulary
Number of subjects: 0
Study 3359863 — intervention group
Group type: COMPARATOR
Intervention: Nondifferential reinforcement for use of the native language or the foreign language
Number of subjects: 0
Study 31605493 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doses of rhEPO combined with iron supplement starting 3 days before surgery (Group A)
Number of subjects: 102
Study 31605493 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doses of rhEPO combined with iron supplement starting the day of surgery (Group B)
Number of subjects: 102
Study 31605493 — intervention group
Group type: COMPARATOR
Intervention: Iron supplement alone (Group C)
Number of subjects: 102
Study 29095982 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 U insulin spray
Number of subjects: 9
Study 29095982 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 U insulin spray
Number of subjects: 9
Study 29095982 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 U insulin spray
Number of subjects: 9
Study 29095982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28399621 — intervention group
Group type: EXPERIMENTAL
Intervention: GAE plus ball game group (BG group; N=30)
Number of subjects: 102
Study 28399621 — intervention group
Group type: EXPERIMENTAL
Intervention: GAE plus square-stepping exercise group (SSE group; N=28)
Number of subjects: 102
Study 28399621 — intervention group
Group type: COMPARATOR
Intervention: General aerobic exercise (GAE) group (N=44)
Number of subjects: 102
Study 24430881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multimedia education in addition to usual care
Number of subjects: 0
Study 24430881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22990092 — intervention group
Group type: COMPARATOR
Intervention: GHRH + Pl
Number of subjects: 21
Study 22990092 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + T
Number of subjects: 21
Study 22990092 — intervention group
Group type: EXPERIMENTAL
Intervention: saline + T
Number of subjects: 21
Study 22990092 — intervention group
Group type: EXPERIMENTAL
Intervention: SS + T
Number of subjects: 21
Study 22990092 — intervention group
Group type: COMPARATOR
Intervention: saline + Pl
Number of subjects: 21
Study 22990092 — intervention group
Group type: COMPARATOR
Intervention: SS + Pl
Number of subjects: 21
Study 21041815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of clear apple juice
Number of subjects: 12
Study 21041815 — intervention group
Group type: COMPARATOR
Intervention: 1 L of clear apple juice without polyphenols (placebo)
Number of subjects: 12
Study 21041815 — intervention group
Group type: COMPARATOR
Intervention: 1 L of cloudy apple juice (positive control)
Number of subjects: 12
Study 21041815 — intervention group
Group type: COMPARATOR
Intervention: 1 L of water (negative control)
Number of subjects: 12
Study 17524030 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, single dose)
Number of subjects: 16
Study 17524030 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 16248381 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium‐99m DTPA aerosol inhalation scintigraphy
Number of subjects: 25
Study 11888095 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg levonorgestrel
Number of subjects: 163
Study 11888095 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg levonorgestrel
Number of subjects: 163
Study 11888095 — intervention group
Group type: COMPARATOR
Intervention: Sequential oral medroxyprogesterone acetate (5mg/day, 14/30 days)
Number of subjects: 163
Study 9457265 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and Regression Trees (CART)
Number of subjects: 885
Study 9457265 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression
Number of subjects: 885
Study 9457265 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of consciousness (LOC)
Number of subjects: 885
Study 9457265 — intervention group
Group type: COMPARATOR
Intervention: Single best performing prognostic factor (level of consciousness)
Number of subjects: 885
Study 8580273 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg
Number of subjects: 3
Study 8580273 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 3
Study 8580273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2636645 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited protein intake (12% of energy)
Number of subjects: 8
Study 2636645 — intervention group
Group type: COMPARATOR
Intervention: Usual protein intake (19% of energy)
Number of subjects: 8
Study 89854 — intervention group
Group type: EXPERIMENTAL
Intervention: shea butter
Number of subjects: 0
Study 89854 — intervention group
Group type: COMPARATOR
Intervention: xylometazoline (control)
Number of subjects: 0
Study 89854 — intervention group
Group type: COMPARATOR
Intervention: white petroleum jelly B.P. (placebo)
Number of subjects: 0
Study 31794673 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Environment (IVE) exergaming (Fruit Ninja)
Number of subjects: 33
Study 31794673 — intervention group
Group type: COMPARATOR
Intervention: Non-Immersive Virtual Environment (non-IVE) exergaming (Fruit Ninja)
Number of subjects: 33
Study 31412864 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback and e-Learning
Number of subjects: 28
Study 31412864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video feedback)
Number of subjects: 28
Study 28351201 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electroconvulsive therapy
Number of subjects: 27
Study 28351201 — intervention group
Group type: COMPARATOR
Intervention: Sham electroconvulsive therapy
Number of subjects: 27
Study 28351201 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 27
Study 24817417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg for two subcutaneous injections at a 15-day interval
Number of subjects: 99
Study 24817417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 23635672 — intervention group
Group type: COMPARATOR
Intervention: General text messages encouraging general pregnancy health
Number of subjects: 204
Study 23635672 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages encouraging general pregnancy health plus influenza vaccination
Number of subjects: 204
Study 20652288 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg oral misoprostol
Number of subjects: 93
Study 20652288 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg sublingual misoprostol
Number of subjects: 93
Study 20298399 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance enhancement training (CET) with salmeterol/fluticasone propionate
Number of subjects: 361
Study 20298399 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (salmeterol/fluticasone propionate)
Number of subjects: 361
Study 20298399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CET and medication alone)
Number of subjects: 361
Study 17219388 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR positive sentinel node
Number of subjects: 39
Study 17219388 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR negative sentinel node
Number of subjects: 39
Study 17219388 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR positive versus RT-PCR negative
Number of subjects: 39
Study 17219388 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR of the sentinel node
Number of subjects: 39
Study 16621879 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (4‐8 mg/day; n = 20)
Number of subjects: 40
Study 16621879 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20‐40 mg/day; n = 20)
Number of subjects: 40
Study 14500052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomization design
Number of subjects: 0
Study 14500052 — intervention group
Group type: COMPARATOR
Intervention: Individual randomization design
Number of subjects: 0
Study 10360914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing 20 microg of ethinylestradiol with 75 microg of gestodene for three cycles
Number of subjects: 26
Study 10360914 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (before treatment)
Number of subjects: 26
Study 7857145 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 732
Study 7857145 — intervention group
Group type: COMPARATOR
Intervention: Sutured anastomoses
Number of subjects: 732
Study 1937993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifecard (10 mg capsules)
Number of subjects: 12
Study 1937993 — intervention group
Group type: COMPARATOR
Intervention: Adalat (10 mg capsules)
Number of subjects: 12
Study 6814596 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxial tomoscintigraphy using iodine‐131‐labelled monoclonal antibodies against carcinoembryonic antigen
Number of subjects: 17
Study 6814596 — intervention group
Group type: COMPARATOR
Intervention: Rectilinear scintigraphy
Number of subjects: 17
Study 30607616 — intervention group
Group type: EXPERIMENTAL
Intervention: p-CREB level
Number of subjects: 107
Study 30607616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no significant cognitive impairment)
Number of subjects: 107
Study 29579158 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG-Denmark
Number of subjects: 4172
Study 29579158 — intervention group
Group type: COMPARATOR
Intervention: Control (local policy for LW and no BCG-Denmark)
Number of subjects: 4172
Study 25529014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HI-CT)
Number of subjects: 83
Study 25529014 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose chemotherapy (CON-CT)
Number of subjects: 83
Study 25529014 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)-only
Number of subjects: 83
Study 25529014 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC)
Number of subjects: 83
Study 25276733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (3 times a day for 4 months)
Number of subjects: 84
Study 25276733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (3 times a day for 4 months)
Number of subjects: 84
Study 25276733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 84
Study 25276733 — intervention group
Group type: COMPARATOR
Intervention: Vitex agnus
Number of subjects: 84
Study 25276733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid and Vitex agnus
Number of subjects: 84
Study 21525683 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic‐polyglycolic acids 50:50 (Fisiograft) alone
Number of subjects: 40
Study 21525683 — intervention group
Group type: COMPARATOR
Intervention: Polylactic‐polyglycolic acids 50:50 in conjunction with polyglactin acid 910 (Vicryl Mesh)
Number of subjects: 40
Study 18246387 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC clamping
Number of subjects: 85
Study 18246387 — intervention group
Group type: COMPARATOR
Intervention: IVC nonclamping
Number of subjects: 85
Study 16428942 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus 5‐fluorouracil (PF)
Number of subjects: 77
Study 16428942 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus 5‐fluorouracil (DF)
Number of subjects: 77
Study 12782435 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine gel
Number of subjects: 13
Study 12782435 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 13
Study 11789275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture‐isoflurane anesthesia (group II)
Number of subjects: 42
Study 11789275 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia (group I)
Number of subjects: 42
Study 9383135 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated computer query with guideline reminder in charts of intervention providers
Number of subjects: 36
Study 9383135 — intervention group
Group type: COMPARATOR
Intervention: No reminder in charts of control providers
Number of subjects: 36
Study 9383135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 36